PressApril 20, 2022 Nue Life Health, a Next-Gen Mental Wellness Platform, Announces a $23M Financing Led by Obvious Ventures and Western Technology Investment
PressApril 19, 2022 Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder
PressApril 18, 2022 Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
PressApril 15, 2022 NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows
PressApril 14, 2022 Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
PressApril 13, 2022 Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other Psychedelic Compounds
PressApril 12, 2022 Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
PressApril 11, 2022 Cybin Announces Publication of International PCT Patent Application for Inhalation Delivery of Multiple Psychedelic Molecules
PressApril 8, 2022 Homecoming Closes $4 Million Seed Funding Round To Scale Psychedelic Therapy Companion Tools
PressApril 7, 2022 PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device Designed to Provide Sustained Control of Elevated Intraocular Pressure
PressApril 5, 2022 Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
PressMarch 31, 2022 Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain
PressMarch 30, 2022 Albert Labs’ Files U.S. Provisional Patent Application for a Cultivation Process for the Production of Psilocybe Mycelia, as well as other Fungi Species
PressMarch 29, 2022 Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
PressMarch 25, 2022 Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06
PressMarch 24, 2022 COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK
PressMarch 22, 2022 Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
